Revolutionizing Cancer Treatment with Peptides
We are working on targeted peptides delivering hope for hematological cancers and solid tumors
Pipeline
PepKon’s pipeline, built on a decade of research, reflects our dedication to advancing therapeutic peptides aimed at treating complex hematologic cancers and select solid tumors, with programs addressing significant medical needs
Peptide
Malignancies
TSP-1/CD47
We are inspired by human biology
PepKon develops innovative peptides derived from the C-terminal domain of thrombospondin-1 (TSP-1). These ten-amino-acid peptides are designed to bind CD47 with high affinity and act as first-in-class agonists.
We have deciphered the MOA
Their unique mechanism triggers caspase independent but calcium dependent immunogenic cell death, selectively targeting cancer cells, including those with resistant or poor prognosis biomarkers.
Therapeutic area
Solid tumors
The second development program for PKT16 extends its application to solid tumors, showing promising in vitro efficacy, especially in challenging cancers like triple-negative breast cancer (TNBC), colorectal cancer, and hepatocellular carcinoma. This expansion broadens PKT16's therapeutic potential beyond hematologic malignancies.
Outlook
Leveraging PepKon's deep expertise in therapeutic peptide research, the company is advancing several promising programs. These initiatives focus on developing next-generation peptides that are even more potent and safety, offering new hope for more effective treatments against difficult-to-treat cancers.
Publications
PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells
Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance
Homotrimerization Approach in the Design of Thrombospondin-1 Mimetic Peptides with Improved Potency in Triggering Regulated Cell Death of Cancer Cells
PKHB1 Tumor Cell Lysate Induces Antitumor Immune System Stimulation and Tumor Regression in Syngeneic Mice with Tumoral T Lymphoblasts
CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells
Thrombospondin‐1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and Structure−Activity Relationship Studies
CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans